Triclosan 2% liquid
An aromatic ether that is phenol which is substituted at C-5 by a chloro group and at C-2 by a 2,4-dichlorophenoxy group.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Triclosan
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Triclosan
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
2 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Surgical site infections: prevention and treatment (NG125)
Plus Sutures for preventing surgical site infection (HTG586)
Secondary bacterial infection of eczema and other common skin conditions: antimicrobial prescribing (NG190)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing all 30 studies.
Reviews & meta-analyses: 9 · 2005–2025
Showing all 30 studies, sorted by most relevant.
I. Ahmed, A. Boulton, S. Rizvi, et al.
BMJ Open, 2019
- Sutures
- Coated Materials, Biocompatible
- Anti-Infective Agents, Local
INTRODUCTION AND OBJECTIVES: Surgical site infections (SSIs) represent a common and serious complication of all surgical interventions. Microorganisms are able to colonise sutures that are implanted in the skin, which is a causative factor of SSIs. Triclosan-coated sutures are antibacterial sutures aimed at reducing SSIs. Our objective is to update the existing literature by systematically reviewing available evidence to assess the effectiveness of triclosan-coated sutures in the prevention of SSIs. METHODS: A systematic review of EMBASE, MEDLINE, AMED (Allied and complementary medicine database) and CENTRAL was performed to identify full text randomised controlled trials (RCTs) on 31 May 2019. INTERVENTION: Triclosan-coated sutures versus non-triclosan-coated sutures. PRIMARY OUTCOME: Our primary outcome was the development of SSIs at 30 days postoperatively. A meta-analysis was performed using a fixed-effects model. RESULTS: Twenty-five RCTs were included involving 11 957 participants. Triclosan-coated sutures were used in 6008 participants and non triclosan-coated sutures were used in 5949. Triclosan-coated sutures significantly reduced the risk of SSIs at 30 days (relative risk 0.73, 95% CI 0.65 to 0.82). Further sensitivity analysis demonstrated that triclosan-coated sutures significantly reduced the risk of SSIs in both clean and contaminated surgery. CONCLUSION: Triclosan-coated sutures have been shown to significantly reduced the risk of SSIs when compared with standard sutures. This is in agreement with previous work in this area. This study represented the largest review to date in this area. This moderate quality evidence recommends the use of triclosan-coated sutures in order to reduce the risk of SSIs particularly in clean and contaminated surgical procedures. PROSPERO REGISTRATION NUMBER: CRD42014014856.
Abstract licence: CC BY-NC
Tinkara Srnovršnik, I. Virant-Klun, B. Pinter
Life, 2023
Exposure to endocrine disrupting chemicals (EDCs) can result in alterations of the female reproductive system, including polycystic ovary syndrome (PCOS). The aim of this review was to summarize the knowledge about the association of EDCs (bisphenols, parabens, and triclosan) with PCOS. We conducted an electronic literature search using PubMed for studies published between January 2007 and October 2022 on EDCs related to PCOS, and evaluated the association of PCOS with bisphenols, parabens and triclosan in 15 articles. Most studies revealed significantly higher plasma, urinary or follicular fluid levels of bisphenol A (BPA) in women with PCOS, and some showed a positive correlation of BPA with insulin resistance, polycystic morphology on ultrasound, hepatic steatosis, bilirubin levels, as well as free androgen index, androstenedione and testosterone serum levels, and markers of low-grade chronic inflammation. There was a negative correlation of BPA with markers of ovarian reserve, sex hormone binding globulin and vitamin D-binding protein. Parabens and triclosan have been studied in only one study each, with no significant associations with PCOS observed. Our review revealed an association of BPA with PCOS and negative effects of BPA on human ovaries; more research is needed to assess the potential associations of parabens and triclosan with PCOS.
Abstract licence: CC BY
Lisa M. Weatherly, J. Gosse
Journal of toxicology and environmental health. Part B, Critical reviews, 2017
- Anti-Infective Agents, Local
- Environmental Pollutants
- Mouthwashes
Zhenyao Wang, Xuan Li, Yi Li, et al.
Environmental pollution, 2024
- Environmental Monitoring
- Triclosan
- Water Pollutants, Chemical
Triclosan, a widely used antimicrobial agent, is frequently detected in aquatic environments, prompting concerns about its toxic effects on aquatic species. Understanding its occurrence and ecological risks is crucial for mitigating triclosan contamination, formulating water quality criteria, and protecting aquatic organisms. This study systematically analyzed triclosan occurrence and ecological risks in surface water across China using the Risk Quotient methodology. A total of 139 and 134 data points were collected for triclosan concentrations and toxicities of aquatic organisms, respectively. Triclosan concentrations in surface water across China ranged from 0.06 to 612 ng/L. Higher triclosan levels were observed in Eastern China compared to Central and Western China, with the average concentration being 4.21- and 7.25-fold higher, respectively. Specifically, the Southeast Rivers Basin (132.98 ng/L) and Pearl River Basin (86.64 ng/L) exhibited maximum triclosan levels, 2.57-19.58 times higher than the other river basins. Further analysis revealed elevated triclosan concentrations in small rivers and surface water within residential areas, with values of 246.1 ng/L in Zhejiang, 86.64 ng/L in Guangdong, 67.58 ng/L in Jiangsu, and 127.99 ng/L in Beijing. Additionally, species sensitivity distribution curves indicated that algae was the most sensitive species to triclosan exposure, followed by invertebrates, while fish exhibited the highest tolerance. The Predicted No-Effect Concentration for the algae, invertebrates, fish, and combined aquatic species were determined to be 0.09, 2.95, 4.44, and 1.51 μg/L, respectively. The occurrence of triclosan in surface water across China did not pose widespread ecological risks. However, targeted monitoring and mitigation efforts are needed, especially in highly developed regions. This study provides crucial insights into the status of triclosan contaminations and risks in China and contributes valuable knowledge to global efforts aimed at safeguarding aquatic ecosystems.
Abstract licence: CC BY
M. Patti, N. Henderson, P. Gajjar, et al.
Environment international, 2021
- Triclosan
- Birth Weight
- Gestational Age
BACKGROUND: Exposure to triclosan, an antimicrobial chemical used in some personal care and cleaning products, has been associated with reduced birth weight in some, but not all epidemiological studies. OBJECTIVES: We conducted a systematic review and meta-analysis to characterize the relation of gestational triclosan exposure with infant birth weight and identify sources of heterogeneity between studies. METHODS: We identified original studies measuring urinary triclosan concentrations during pregnancy and reporting their association with infant birth weight, gestational age (GA) adjusted birth weight (g), or GA-standardized birth weight z-scores. Using a random effects model, we estimated differences in these outcomes per 10-fold increase in triclosan concentrations and considered triclosan levels and infant sex as sources of heterogeneity. Using Navigation Guide Methods, we evaluated risk of bias within individual studies and across the body of evidence. RESULTS: Among thirteen studies, median triclosan concentrations varied by almost 2-orders of magnitude (0.6-29 ng/mL), with higher concentrations in North American and some European studies compared to Asian ones. Associations between triclosan and birth weight (β:-20 g; 95% CI:-65, 26; n = 6) were stronger than those for GA-adjusted birth weight (β:-12 g; 95% CI:-29, 5; n = 9). Triclosan was not associated with GA-standardized birth weight z-scores (β:-0.04; 95% CI:-0.16, 0.07; n = 5). The association between triclosan and GA-adjusted birth weight was stronger in studies with median triclosan values ≥10 ng/mL compared to studies with median values < 10 ng/mL (β:-27 g; 95% CI:-61, 7; n = 4 vs. β:6g; 95% CI:-20, 31; n = 5). With a limited number of studies, we observed suggestive evidence that inverse associations were more apparent in studies with ≥ 2 prospective triclosan measures compared to those with one measure. DISCUSSION: Available evidence, with "low" risk of bias, provides limited evidence that triclosan exposure and reduces infant birth weight. We observed stronger inverse associations between triclosan concentrations and birth weight in populations with higher triclosan exposure.
Abstract licence: CC BY-NC-ND
Mohammad A. Alfhili, M. Lee
Oxidative Medicine and Cellular Longevity, 2019
- Disinfectants
- Triclosan
- Signal Transduction
Triclosan (TCS) is a synthetic, chlorinated phenolic antimicrobial agent commonly used in commercial and healthcare products. Items made with TCS include soaps, deodorants, shampoos, cosmetics, textiles, plastics, surgical sutures, and prosthetics. A wealth of information obtained from in vitro and in vivo studies has demonstrated the therapeutic effects of TCS, particularly against inflammatory skin conditions. Nevertheless, extensive investigations on the molecular aspects of TCS action have identified numerous adversaries associated with the disinfectant including oxidative injury and influence of physiological lifespan and longevity. This review presents a summary of the biochemical alterations pertaining to TCS exposure, with special emphasis on the diverse molecular pathways responsive to TCS that have been elucidated during the present decade.
Abstract licence: CC BY
Kai Bester
Archives of Environmental Contamination and Toxicology, 2005
- Environmental Monitoring
- Waste Disposal, Fluid
- Germany
M. Sinicropi, D. Iacopetta, J. Ceramella, et al.
Antibiotics, 2022
toothpaste, containing 10 mM TCS, is effective in controlling biofilm formation and maintaining gingival health. Given its broad usage, TCS is present ubiquitously in the environment. Given its strong lipophilicity and accumulation ability in organisms, it is potentially harmful to biohealth. Several reports suggest the toxicity of this compound, which is inserted in the class of endocrine disrupting chemicals (EDCs). In September 2016, TCS was banned by the U.S. Food and Drug Administration (FDA) and the European Union in soap products. Despite these problems, its application in personal care products within certain limits is still allowed. Today, it is still unclear whether TCS is truly toxic to mammals and the adverse effects of continuous, long-term, and low concentration exposure remain unknown. Indeed, some recent reports suggest the use of TCS as a repositioned drug for cancer treatment and cutaneous leishmaniasis. In this scenario it is necessary to investigate the advantages and disadvantages of TCS, to understand whether its use is advisable or not. This review intends to highlight the pros and cons that are associated with the use of TCS in humans.
Abstract licence: CC BY
B. Czech, Magdalena Kończak, M. Rakowska, et al.
Journal of Cleaner Production, 2021
Limei Sun, Yuhang Ling, Jiahui Jiang, et al.
Chemosphere, 2020
- RNA-Seq
- Bisphenol A Compounds
- Benzhydryl Compounds
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
21 h
Mechanism
Triclosan is a biocidal compound with multiple targets in the cytoplasm and membrane.
Food interactions
None known
Human targets
6 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
[A7171]…
Half-life
21 h
[A263242]
Metabolism
Elimination
12%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
How the body processes this drug — absorption, distribution, metabolism, and elimination
[A7171]
Triclosan is rapidly absorbed and distributed in the human body.
[A263242]
Maximum concentrations are reached within three hours after oral intake. However, the metabolism and excretion of the compound is fast.
[A263242]
[A263242]
[A7171]
Proteins and enzymes this drug interacts with in the body
PMID:1378832
NO mediates vascular endothelial growth factor (VEGF)-induced angiogenesis in coronary vessels and promotes blood clotting through the activation of platelets
Response to specific ligands is species-specific. Activated by naturally occurring steroids, such as pregnenolone and progesterone. Binds to a response element in the promoters of the CYP3A4 and ABCB1/MDR1 genes
PMID:19022849
Transcription factor activity is modulated by bound coactivator and corepressor proteins like ZBTB7A that recruits NCOR1 and NCOR2 to the androgen response elements/ARE on target genes, negatively regulating androgen receptor signaling and androgen-induced cell proliferation .
PMID:20812024
Transcription activation is also down-regulated by NR0B2. Activated, but not phosphorylated, by HIPK3 and ZIPK/DAPK3
Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses.
Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity)
ATC D08AE04
ATC D09AA06
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Triclosan
Additional database identifiers
Drugs Product Database (DPD)
2813
ChemSpider
5363
BindingDB
8726
PDB
TCL
ZINC
ZINC000000002216
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7876
GenAtlas
NOS3
GeneCards
NOS3
GenBank Gene Database
M93718
GenBank Protein Database
189212
Guide to Pharmacology
1249
UniProt Accession
NOS3_HUMAN
GenBank Gene Database
X78733
GenBank Protein Database
587106
UniProt Accession
FABI_ECOLI
UniProt Accession
INHA_MYCTU
GenBank Gene Database
AE000511
GenBank Protein Database
2313282
UniProt Accession
FABI_HELPY
UniProt Accession
A0A6L8PBX8_BACAN
GenBank Gene Database
BX571856
GenBank Protein Database
49240383
UniProt Accession
FABI_STAAR
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7968
GenAtlas
NR1I2
GeneCards
NR1I2
GenBank Gene Database
AF061056
GenBank Protein Database
3511138
Guide to Pharmacology
606
UniProt Accession
NR1I2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:644
GenAtlas
AR
GeneCards
AR
GenBank Gene Database
M20132
GenBank Protein Database
178628
Guide to Pharmacology
628
UniProt Accession
ANDR_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:7969
GeneCards
NR1I3
GenBank Gene Database
Z30425
GenBank Protein Database
458542
Guide to Pharmacology
607
UniProt Accession
NR1I3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:9236
GenAtlas
PPARG
GeneCards
PPARG
GenBank Gene Database
U79012
GenBank Protein Database
1711117
Guide to Pharmacology
595
UniProt Accession
PPARG_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12015
GenAtlas
TPO
GeneCards
TPO
GenBank Gene Database
J02969
GenBank Protein Database
339867
Guide to Pharmacology
2526
UniProt Accession
PERT_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
Linked open data from Wikidata (Q408646), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.